Related Media

Drug-induced immune hemolytic anemia

Definition

Drug-induced immune hemolytic anemia is a blood disorder that occurs when a medicine triggers the body's defense (immune) system to attack its own red blood cells. This causes red blood cells to break down earlier than normal.

See also: Hemolytic anemia

Alternative Names

Immune hemolytic anemia secondary to drugs; Anemia - immune hemolytic - secondary to drugs

Causes, incidence, and risk factors

In some cases, a drug can cause the immune system to mistakenly think your own red blood cells are dangerous, foreign substances. Antibodies then develop against the red blood cells. The antibodies attach to red blood cells and cause them to break down too early.

Drugs that can cause this type of hemolytic anemia include:

  • Cephalosporins (a class of antibiotics)
  • Levodopa
  • Methyldopa
  • Penicillin and its derivatives
  • Quinidine
  • Some nonsteroidal anti-inflammatory drugs (NSAIDs)

There are many other rarer causes of drug-induced hemolytic anemia. This includes hemolytic anemia associated with glucose-6 phosphate dehydrogenase (G6PD) deficiency. But in this case, the breakdown of red blood cells is due to a certain type of stress in the cell, not the body's immune system.

Drug-induced hemolytic anemia is rare in children.

Symptoms

Signs and tests

A physical examination may show an enlarged spleen. A number of blood and urine tests may be done to help diagnose this condition.

Tests may include:

Treatment

Stopping the drug that is causing the problem may relieve or control the symptoms.

Some persons may be given a medicine called prednisone to reduce the immune response against the red blood cells. Special blood transfusions may be needed to treat severe symptoms.

Support Groups

Expectations (prognosis)

Most patients have a good outcome if they stop taking the drug that is causing the problem.

Complications

Death caused by severe anemia is rare.

Calling your health care provider

See your health care provider if you have symptoms of this condition.

Prevention

You should continue to avoid the drug that caused this condition.

References

Schwartz R. Autoimmune and intravascular hemolytic anemia. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier;2007:chap 164.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).